

Dr. Lal PathLabs Limited records growth of 21% in Q3 FY2015-16

New Delhi, India, February 13, 2016 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces its Q3 and 9 Months financial performance of FY2015-16 in accordance with Indian GAAP.

Consolidated Performance Highlights: Q3FY2016 vs. Q3FY2015

- Total Revenue increased by 21% Y-o-Y to Rs. 1886 million
- EBITDA increased to Rs. 427 million from Rs 405 million without considering ESOP charge reversal. After ESOP reversals EBITDA increased to Rs701 million.
- EBITDA Margins 22.6% without considering impact of ESOP reversals but after absorbing mark to market cost of ESPS (Stock Grant Scheme) of Rs 32 million and prior period charge on account of payment of statutory bonus of Rs 16 million. Without these charges the margin would be 25.2%
- Profit after Tax increased to Rs. 611 million;
- EPS for the quarter was Rs 7.31(diluted)

Consolidated Performance Highlights: 9 Months FY2016 vs. 9 Months FY2015

- Total Revenue increased by 22% Y-o-Y to Rs. 5936 million
- EBITDA increased by 12% Y-o-Y to Rs. 1521 million;
- EBITDA Margins 25.6% without considering ESOP reversals.
- Profit after Tax increased by 46% to Rs. 986 million; Margins of 17%
- YTD EPS was Rs 11.83 (diluted)

Commenting on the results and performance, **Dr. Arvind Lal, Chairman and Managing Director** said:

I am delighted to be sharing the first financial and operating performance of the Company as a listed entity and I extend a warm welcome to our public shareholders. I am proud to share that all of us at LPL have very meticulously built-up a very scalable model in one of the fastest growing segment of the healthcare industry. The trend is tilting in favour of established players like LPL who with world-class infrastructure and modern logistics and IT infrastructure have demonstrated a progressive scale-up in operations.

I am pleased with the reported growth this year which is in line with our plan. For us the future is even more exciting and given our expanding presence, strong brand, solid financial position combined with a committed team that is focused on providing best quality services to our patients and resultantly driving growth. I am sure that the business will continue to create significant value for all our stakeholders."

Financial Overview

Particulars (Rs. mn)	Q3 FY16	Q3 FY15	Growth %	9M FY16	9M FY15	Growth %
Total Revenues	1,885.7	1,558.3	21.0%	5,936.1	4,877.5	21.7%
Total Expenditure	1,185.1	1,175.5	0.8%	4,380.2	3,755.8	16.6%
EBITDA	700.6	382.8	83.0%	1,555.9	1,121.7	38.7%
EBITDA (without ESOP reversal)	426.8	405.3	5.3%	1,521.2	1,359.2	11.9%
<i>Margins</i>	<i>22.6%</i>	<i>26.0%</i>	<i>(340) bps</i>	<i>25.6%</i>	<i>27.9%</i>	<i>(230) bps</i>
PBT *	670.0	341.6	96.1%	1,479.4	1,006.8	46.9%
PBT (without ESOP reversal)	396.2	364.1	8.8%	1,444.7	1,244.3	16.1%
<i>Margins</i>	<i>21.0%</i>	<i>23.4%</i>	<i>(240) bps</i>	<i>24.3%</i>	<i>25.5%</i>	<i>(120) bps</i>
PAT	611.1	228.5	167.4%	985.8	676.8	45.7%
EPS (Diluted)	7.31	2.77	163.9%	11.83	8.18	44.6%

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal PathLabs has built a national, "hub and spoke" network that includes its National Reference Laboratory in New Delhi, 171 other clinical laboratories, 1,554 patient service centers and over 7,000 pickup points as of September 30, 2015. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Rajat kalra
Dr. Lal PathLabs Limited

+91 124 4698400
Rajat.Kalra@lalpathlabs.com

Aparna Agarwal
Adfactors PR

+917838116613
aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.